Literature DB >> 18086277

Varicella zoster virus-associated disease in adult kidney transplant recipients: incidence and risk-factor analysis.

T Arness1, R Pedersen, R Dierkhising, W Kremers, R Patel.   

Abstract

Varicella zoster virus (VZV)-related disease, particularly herpes zoster, is a complication of organ transplantation due to long-term immunosuppression. We determined the incidence and risk factors for post-transplant VZV infection by retrospectively reviewing the medical records of a cohort of 612 adult renal transplant recipients transplanted at Mayo Clinic Rochester between October 1, 2001 and October 1, 2004. Thirty-seven subjects developed herpes zoster, corresponding to a follow-up time-adjusted incidence of 11.2% at 4 years post transplant. The incidence rate of zoster was relatively constant between 6 months and 4 years, yielding an average incidence of approximately 28 per 1000 person-years. The risk of developing post-transplant zoster increased with increasing age at transplant, with each decade conferring a 1.42-fold (P=0.009) increase in risk of zoster development. Seronegativity at time of transplant conferred over 3 times the risk of development of post-transplant zoster (hazard ratio 3.4; P=0.04) compared with seropositivity. Adult kidney transplant recipients are at high risk for the development of post-transplant zoster.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18086277     DOI: 10.1111/j.1399-3062.2007.00289.x

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  19 in total

1.  Considerations for a Primary Care Physician Assistant in Treating Kidney Transplant Recipients.

Authors:  Ryan Aston; Allison Durkin; Kristen Harris; Amanda Mace; Sierra Moore; Brittany Smith; Eric Soult; Mara Wright; Dustin Yothers; Derrick L Latos; Joseph Horzempa
Journal:  Qual Prim Care       Date:  2015

2.  Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients.

Authors:  S A Pergam; C W Forsberg; M J Boeckh; C Maynard; A P Limaye; A Wald; N L Smith; B A Young
Journal:  Transpl Infect Dis       Date:  2011-02       Impact factor: 2.228

3.  Varicella zoster virus (VZV) in solid organ transplant recipients.

Authors:  S A Pergam; A P Limaye
Journal:  Am J Transplant       Date:  2009-12       Impact factor: 8.086

4.  Incidence and risk factors for herpes zoster following heart transplantation.

Authors:  S Koo; L S Gagne; P Lee; P P Pratibhu; L M James; M M Givertz; F M Marty
Journal:  Transpl Infect Dis       Date:  2013-10-23       Impact factor: 2.228

5.  Varicella zoster virus in solid organ transplantation.

Authors:  S A Pergam; A P Limaye
Journal:  Am J Transplant       Date:  2013-03       Impact factor: 8.086

6.  Herpes Zoster Risk in Immunocompromised Adults in the United States: A Systematic Review.

Authors:  Susannah L McKay; Angela Guo; Steven A Pergam; Kathleen Dooling
Journal:  Clin Infect Dis       Date:  2020-10-23       Impact factor: 9.079

7.  Systematic Review and Meta-analysis of Herpes Zoster Vaccine in Patients With CKD.

Authors:  Mohamad A Hamad; Hilda Allam; Ashna Sulaiman; Karumathil Murali; Hicham I Cheikh Hassan
Journal:  Kidney Int Rep       Date:  2021-03-03

8.  Skin and soft tissue infections in the transplant population.

Authors:  Camille Nelson Kotton
Journal:  Curr Infect Dis Rep       Date:  2008-09       Impact factor: 3.663

9.  Incidence and risk factors of herpes zoster among adult renal transplant recipients receiving universal antiviral prophylaxis.

Authors:  Ioanna D Pavlopoulou; Stavroula Poulopoulou; Christina Melexopoulou; Ioanna Papazaharia; George Zavos; Ioannis N Boletis
Journal:  BMC Infect Dis       Date:  2015-07-24       Impact factor: 3.090

Review 10.  Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials.

Authors:  Marta López-Fauqued; Maribel Co-van der Mee; Adriana Bastidas; Pierre Beukelaers; Alemnew F Dagnew; Juan Jose Fernandez Garcia; Anne Schuind; Fernanda Tavares-da-Silva
Journal:  Drug Saf       Date:  2021-06-11       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.